Crispr Stem & Therapeutics (CST)

Company Overview

Snapshot

Founded in May 2018 by Dr. Dalia El-Ani, Crispr Stem & Therapeutics (CST) operates with 1–10 employees. The company has raised $100K across one funding round. In January 2020, Crispr Stem & Therapeutics (CST) secured a grant from the Israel Innovation Authority.

Business overview

Crispr Stem & Therapeutics (CST) is a Health Tech & Life Sciences company focused on developing gene and cell therapy solutions for acute myocardial ischemia and chronic heart failure. The company's core technology involves a patented cardio-protective CRISPR-based stem cell protocol to genetically modify a patient's own stem cells. These modified cells are then implanted to restrict heart damage, aiming to improve patient life expectancy and recovery, shorten hospitalization, and eliminate rejection risks. CST operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting healthcare providers and the biotechnology segment of life sciences.

Company Intelligence Q&A

What is Crispr Stem & Therapeutics (CST)'s primary focus?

Crispr Stem & Therapeutics (CST) is developing a patented cardio-protective CRISPR-based stem cell protocol designed to limit heart damage following acute heart attacks and chronic heart failure.

When was Crispr Stem & Therapeutics (CST) founded?

Crispr Stem & Therapeutics (CST) was founded in May 2018.

Who is the founder of Crispr Stem & Therapeutics (CST)?

Dr. Dalia El-Ani is the founder and CEO of Crispr Stem & Therapeutics (CST).

What type of funding has Crispr Stem & Therapeutics (CST) received?

Crispr Stem & Therapeutics (CST) received a grant from the Israel Innovation Authority in January 2020.

What is the total disclosed funding raised by Crispr Stem & Therapeutics (CST)?

Crispr Stem & Therapeutics (CST) has raised a total of $100K across one funding round.